Sector News

AbbVie’s $21B buyout puts Pharmacyclics execs in line for $4B payoff

March 24, 2015
Life sciences
Pharmacyclics CEO Robert Duggan would add $3.5 billion to his already substantial wealth, if and when AbbVie’s $21 billion buyout goes through. But considering Duggan’s record, a multibillion-dollar payoff is to be expected. It’s the other executives and directors–who together qualify for more than $575 million–who could inspire M&A envy.
 
COO Mahkam Zanganeh, for instance, would rack up severance of $48 million, provided she’s squeezed out within two years of the merger. That includes compensation for the tax bill she’d have to pay on her windfall. More immediately–and certainly–she’ll reap a hefty $224.6 million for her shares and options, according to an SEC filing about the merger. Not bad for 6 years’ work at the biotech.
 
But that equity payoff also rewards Zanganeh for tagging Pharmacyclics as an investment target for Duggan in the first place, as her official bio points out. And a big chunk of that amount comes from the 428,281 shares Zanganeh already owns–a stake worth almost $119 million in the merger. The remaining millions come from share awards and options that were part of her compensation.
 
Pharmacyclics execs who don’t already own major stakes in the company will still enjoy quite sizable windfalls. CFO Manmeet Soni, for instance, stands to get $29.8 million for his equity, $15 million in cash for his options and $14 million for stock awards. And if he’s in line for a severance payoff almost as big as Zanganeh’s at $46 million, provided he’s terminated or leaves “for good reason,” under the company’s severance policy.
 
And Chief Commercial Officer Shawn Tomasello–who just joined Pharmacyclics last year from Celgene–is up for $28 million in severance herself. Plus almost $29 million for her equity with $26 million of that from options and share awards.
 
The moral of this story? We’d say the point is that M&A pays off for the execs involved. But that’s obvious. The real takeaway? Get a job at Duggan’s next venture.
 
By Tracy Staton
 

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach